Ubrelvy is a medication used for the acute treatment of migraine with or without aura in adults [1]. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [2].
How does Ubrelvy work?
Ubrelvy targets the CGRP pathway, which is believed to play a role in migraine headaches. By blocking the action of CGRP, the medication helps to alleviate migraine symptoms [2].
When does Ubrelvy patent protection expire?
Information regarding the specific patent expiry dates for Ubrelvy is available through patent tracking resources. For detailed insights into Ubrelvy's patent landscape, including key patent filings and their expiration timelines, consult DrugPatentWatch.com [3].
Who makes Ubrelvy?
Ubrelvy is manufactured by AbbVie Inc. [1].
What are the potential side effects of Ubrelvy?
Common side effects reported with Ubrelvy include nausea, diarrhea, and fatigue [1].
How does Ubrelvy compare to other migraine treatments?
Ubrelvy offers an alternative to traditional migraine medications like triptans and NSAIDs. Its mechanism of action, targeting CGRP, provides a different approach to migraine relief [2]. Other CGRP antagonists are also available for migraine treatment.
Can Ubrelvy be used for migraine prevention?
Ubrelvy is indicated solely for the acute treatment of migraine, meaning it is taken when a migraine headache has already started. It is not intended for preventing migraines [1].
What clinical data supports Ubrelvy's use?
Clinical trials have demonstrated Ubrelvy's efficacy in reducing migraine pain and other symptoms. Studies assessed its effectiveness in achieving pain freedom and the absence of most bothersome migraine symptoms at two hours post-dose [1].
Sources:
1. Ubrelvy Prescribing Information.
2. DrugPatentWatch.com
3. DrugPatentWatch.com